FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1529201210> ?p ?o ?g. }

• W1529201210 endingPage "9" @default.
• W1529201210 startingPage "1121" @default.
• W1529201210 abstract "Neoadjuvant chemotherapy in breast cancer corresponds to the use of a systemic treatment applied before loco-regional treatment (surgery and/or radiotherapy). Initiated in the seventies for treatment of the locally advanced and/or inflammatory breast cancers, induction chemotherapy has been extended in the beginning of eighties for cancers known as operable (size higher than 3 cm and/or in central position) in order to allow a more frequent conservating surgery. This objective is obtained in 75% of the cases approximately without increase in the risk of local relapse and without noxious effect on overall survival, in spite of the delay of the loco-regional treatment. Neo-adjuvant chemotherapy progressively moved with the advent of major drugs in breast cancer which are anthracyclins, vinorelbine and taxans. But to date, no protocol was essential like an uncontested standard. However, it seems that obtaining a complete clinical response is the best guarantor to avoid relapse. That seems to be observed only after 6 cycles, even 8 cycles of chemotherapy, each cycle combining the 2 major drugs for the treatment of breast cancer of which are anthracyclins and taxanes employed according a sequential scheme after a based-anthracyclins treatment, except any cardiac contra-indication. Moreover, the use of targeted therapeuticals like Herceptin, with a chemotherapy, seems to be promising and should be more studied. Finally, when a neoadjuvant chemotherapy is administered, the evaluation of the pre-treatment biopsy helps to establish key patient-management parameters such as tumour type, SBR grade and immunohistochemical parameters. This evaluation provides predictive parameters with regards to drug response (hormonal status, overexpression of Her2). The further studies realised in this way will permit to improve the results yet obtained." @default.
• W1529201210 created "2016-06-24" @default.
• W1529201210 creator A5003470485 @default.
• W1529201210 creator A5011740740 @default.
• W1529201210 creator A5029086962 @default.
• W1529201210 creator A5030260555 @default.
• W1529201210 creator A5064377722 @default.
• W1529201210 creator A5069540694 @default.
• W1529201210 creator A5077857574 @default.
• W1529201210 creator A5079006574 @default.
• W1529201210 creator A5084745289 @default.
• W1529201210 creator A5086724383 @default.
• W1529201210 date "2006-11-01" @default.
• W1529201210 modified "2023-10-18" @default.
• W1529201210 title "[Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer]." @default.
• W1529201210 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17145582" @default.
• W1529201210 hasPublicationYear "2006" @default.
• W1529201210 type Work @default.
• W1529201210 sameAs 1529201210 @default.
• W1529201210 citedByCount "2" @default.
• W1529201210 countsByYear W15292012102012 @default.
• W1529201210 crossrefType "journal-article" @default.
• W1529201210 hasAuthorship W1529201210A5003470485 @default.
• W1529201210 hasAuthorship W1529201210A5011740740 @default.
• W1529201210 hasAuthorship W1529201210A5029086962 @default.
• W1529201210 hasAuthorship W1529201210A5030260555 @default.
• W1529201210 hasAuthorship W1529201210A5064377722 @default.
• W1529201210 hasAuthorship W1529201210A5069540694 @default.
• W1529201210 hasAuthorship W1529201210A5077857574 @default.
• W1529201210 hasAuthorship W1529201210A5079006574 @default.
• W1529201210 hasAuthorship W1529201210A5084745289 @default.
• W1529201210 hasAuthorship W1529201210A5086724383 @default.
• W1529201210 hasConcept C121608353 @default.
• W1529201210 hasConcept C126322002 @default.
• W1529201210 hasConcept C141071460 @default.
• W1529201210 hasConcept C143998085 @default.
• W1529201210 hasConcept C2776694085 @default.
• W1529201210 hasConcept C2778239845 @default.
• W1529201210 hasConcept C2779786085 @default.
• W1529201210 hasConcept C2780350996 @default.
• W1529201210 hasConcept C509974204 @default.
• W1529201210 hasConcept C530470458 @default.
• W1529201210 hasConcept C71924100 @default.
• W1529201210 hasConceptScore W1529201210C121608353 @default.
• W1529201210 hasConceptScore W1529201210C126322002 @default.
• W1529201210 hasConceptScore W1529201210C141071460 @default.
• W1529201210 hasConceptScore W1529201210C143998085 @default.
• W1529201210 hasConceptScore W1529201210C2776694085 @default.
• W1529201210 hasConceptScore W1529201210C2778239845 @default.
• W1529201210 hasConceptScore W1529201210C2779786085 @default.
• W1529201210 hasConceptScore W1529201210C2780350996 @default.
• W1529201210 hasConceptScore W1529201210C509974204 @default.
• W1529201210 hasConceptScore W1529201210C530470458 @default.
• W1529201210 hasConceptScore W1529201210C71924100 @default.
• W1529201210 hasIssue "11" @default.
• W1529201210 hasLocation W15292012101 @default.
• W1529201210 hasOpenAccess W1529201210 @default.
• W1529201210 hasPrimaryLocation W15292012101 @default.
• W1529201210 hasVolume "93" @default.
• W1529201210 isParatext "false" @default.
• W1529201210 isRetracted "false" @default.
• W1529201210 magId "1529201210" @default.
• W1529201210 workType "article" @default.